NasdaqCM - Delayed Quote USD

Equillium, Inc. (EQ)

0.4790

+0.0230

+(5.04%)

At close: April 11 at 4:00:00 PM EDT

Promising Penny Stocks To Consider In April 2025

Amid ongoing tariff uncertainties and volatile trading, the U.S. stock market is experiencing significant fluctuations, with major indices like the Dow Jones Industrial Average and S&P 500 facing substantial declines. In such a turbulent landscape, investors may find opportunities in penny stocks—an investment category that, despite its outdated name, continues to offer potential value. By focusing on companies with robust financials and clear growth trajectories, investors might uncover...

Simply Wall St. 6 days ago

ISPR

EQ
+5.04%
BWEN
Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Equillium (EQ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks 12 days ago

EQ
+5.04%
Equillium Full Year 2024 Earnings: Beats Expectations

Equillium ( NASDAQ:EQ ) Full Year 2024 Results Key Financial Results Revenue: US$41.1m (up 14% from FY 2023). Net loss...

Simply Wall St. 16 days ago

EQ
+5.04%
Equillium pushes for breakthrough status despite missing primary endpoint

Despite missing its primary endpoint, Equillium is pushing ahead with itolizumab citing its complete response by day 99.

Clinical Trials Arena 17 days ago

EQ
+5.04%
GLDAF
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

LA JOLLA, Calif., March 27, 2025--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced topline data from the Phase 3 EQUATOR study evaluating itolizumab in first-line treatment of patients with acute graft-versus-host disease (aGVHD). The study results did not demonstrate a meaningful difference in complete response (CR) or overall

Business Wire 17 days ago

EQ
+5.04%
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

LA JOLLA, Calif., March 27, 2025--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2024, as well as corporate and clinical highlights.

Business Wire 17 days ago

EQ
+5.04%
Are Medical Stocks Lagging Aveanna Healthcare (AVAH) This Year?

Here is how Aveanna Healthcare (AVAH) and Equillium, Inc. (EQ) have performed compared to their sector so far this year.

Zacks 30 days ago

AVAH

EQ
+5.04%
Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now

Equillium (EQ) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks last month

EQ
+5.04%
Equillium (EQ) Upgraded to Buy: Here's What You Should Know

Equillium (EQ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 2 months ago

EQ
+5.04%
Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock

Equillium (EQ) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks 2 months ago

EQ
+5.04%
CuriosityStream And 2 Other Promising Penny Stocks On US Exchange

As the S&P 500 inches toward a record high and investors digest a flurry of earnings reports, the spotlight on smaller market players has intensified. Penny stocks, while often considered relics of past market eras, continue to offer intriguing opportunities for those willing to explore beyond the major indices. Typically associated with smaller or newer companies, these stocks can present an appealing mix of affordability and growth potential when backed by strong financials.

Simply Wall St. 2 months ago

CURI

CURIW

EQ
+5.04%
Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge

Itolizumab achieved a clinical remission rate of 23.3% in ulcerative colitis patients.

GuruFocus.com 2 months ago

EQ
+5.04%
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

LA JOLLA, Calif., February 06, 2025--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, and Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceutical company, today announced positive topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ulcerative colitis (UC).

Business Wire 2 months ago

BIOCON.NS

EQ
+5.04%
BIOCON.BO
US Penny Stocks To Watch In January 2025

As the U.S. market looks to rebound from a late-2024 slump, major indices like the S&P 500 and Nasdaq Composite have started 2025 with slight gains, hinting at potential recovery. Penny stocks, often representing smaller or newer companies, continue to offer intriguing opportunities despite being considered a throwback term. By focusing on those with strong financials and clear growth prospects, investors can uncover hidden value in these lesser-known stocks.

Simply Wall St. 3 months ago

EQ
+5.04%
RLMD

IMPP
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

LA JOLLA, Calif., November 13, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2024 and provided corporate and clinical updates.

Business Wire 4 months ago

EQ
+5.04%
Equillium to Present at the Stifel Healthcare Conference

LA JOLLA, Calif., November 13, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Stifel Healthcare Conference taking place in New York on November 18 & 19, 2024.

Business Wire 4 months ago

EQ
+5.04%
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

LA JOLLA, Calif., November 12, 2024--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that a poster was presented over the weekend at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The conference took place at the George R. Brown Convention Center in Houston, Texas from November 6 to 10, 2024.

Business Wire 4 months ago

EQ
+5.04%
Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth

Equillium (EQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 5 months ago

EQ
+5.04%
SPRO
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates

Travere (TVTX) delivered earnings and revenue surprises of 0% and 4.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

EQ
+5.04%
Equillium Maintains Rights to Itolizumab Following Ono Partnership

LA JOLLA, Calif., October 31, 2024--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Ono Pharmaceutical Co., Ltd. (Ono) has made the strategic business decision to allow its option to acquire Equillium’s rights to itolizumab to expire. The decision was not related to data from any clinical program and there have been no obse

Business Wire 5 months ago

EQ
+5.04%

Performance Overview

Return	EQ	S&P 500 (^GSPC)
YTD	-36.13%	-8.81%
1-Year	-75.44%	+3.16%
3-Year	-84.60%	+21.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Equillium, Inc. (EQ)

Promising Penny Stocks To Consider In April 2025

Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Equillium Full Year 2024 Earnings: Beats Expectations

Equillium pushes for breakthrough status despite missing primary endpoint

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

Are Medical Stocks Lagging Aveanna Healthcare (AVAH) This Year?

Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now

Equillium (EQ) Upgraded to Buy: Here's What You Should Know

Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock

CuriosityStream And 2 Other Promising Penny Stocks On US Exchange

Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

US Penny Stocks To Watch In January 2025

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Equillium to Present at the Stifel Healthcare Conference

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Performance Overview